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Abstract
Background: We have developed multiple stable cell lines containing subgenomic HCV RNA that are resistant to treatment
with interferon alpha (IFN-a. Characterization of these IFN-a resistant replicon cells showed defects in the phosphorylation
and nuclear translocation of STAT1 and STAT2 proteins due to a defective Jak-STAT pathway.
Methodology/Principal Findings: In this study, we have developed an alternative strategy to overcome interferon
resistance in a cell culture model by improving intracellular STAT1 signaling. An engineered STAT1-CC molecule with double
cysteine substitutions in the Src-homology 2 (SH2) domains of STAT1 (at Ala-656 and Asn-658) efficiently phosphorylates
and translocates to the nucleus of IFN-resistant cells in an IFN-c dependent manner. Transfection of a plasmid clone
containing STAT1-CC significantly activated the GAS promoter compared to wild type STAT1 and STAT3. The activity of the
engineered STAT1-CC is dependent upon the phosphorylation of tyrosine residue 701, since the construct with a
substituted phenylalanine residue at position 701 (STAT1-CC-Y701F) failed to activate GAS promoter in the replicon cells.
Intracellular expression of STAT1-CC protein showed phosphorylation and nuclear translocation in the resistant cell line after
IFN-c treatment. Transient transfection of STAT1-CC plasmid clone into an interferon resistant cell line resulted in inhibition
of viral replication and viral clearance in an IFN-c dependent manner. Furthermore, the resistant replicon cells transfected
with STAT1-CC constructs significantly up regulated surface HLA-1 expression when compared to the wild type and Y to F
mutant controls.
Conclusions: These results suggest that modification of the SH2 domain of the STAT1 molecule allows for improved IFN-c
signaling through increased STAT1 phosphorylation, nuclear translocation, HLA-1 surface expression, and prolonged
interferon antiviral gene activation.
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Introduction
Hepatitis C virus (HCV) infection is a major public health
concern with a prevalence of approximately 3% of the world
population chronically infected by the virus [1]. Approximately
70% of patients that are infected with HCV develop a chronic
infection of the liver. Interferon alpha (IFN-a combined with
ribavirin is the standard treatment option for chronic HCV
infection, however the majority of patients are unable to clear the
infection with this therapy [2,3]. These chronically infected HCV
patients experience a slow progressive disease of the liver that can
result in end stage liver disease such as liver cirrhosis and
hepatocellular carcinoma [4]. In the United States HCV infection
is the leading cause of death from liver disease and the number one
indication for liver transplant [5]. Currently there are no effective
drug therapies available for liver cirrhosis or hepatocellular
carcinoma, therefore the development of an antiviral approach
to cure chronic HCV infection is essential.
The interferons are a super family of proteins secreted by
human cells that manifest multiple functions in the human body
such as protection of cells from viral infection, regulation of cell
growth, and modulation of the immune system [6]. IFN-a/b also
known as type 1 interferon, binds to cell surface receptors
consisting of two separate proteins, IFNAR1 and IFNAR2 [7].
High levels of IFNAR1 and IFNAR2 are expressed in human liver
cells thus providing a clear rationale for the treatment of chronic
HCV infection with IFN-a [8,9]. The binding of IFN-a to cell
surface receptors activates a cascade of signal transduction
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kinases, Janus kinase 1 (Jak1) and tyrosine kinase 2 (Tyk2). These
kinases phosphorylate IFNAR1, which then serve as a docking site
for the Src-homology domain 2 of the signal transducer and
activator of transcription factor 2 (STAT2), which is then
phosphorylated by Tyk2 on tyrosine residue 690. The other
STAT proteins including STAT1 are subsequently recruited to the
cell membrane for phosphorylation and activation. Activated
STAT1 and STAT2 monomers are then disassociate from the
receptor and form a heterodimer that interacts with interferon
regulatory factor 9 (p48) to form an active transcription complex
called IFN-stimulated gene factor 3. This complex translocates
into the nucleus and binds to a consensus DNA sequence to
initiate antiviral gene transcription. The molecular cascade of
events initiated following IFN binding to its receptor in normal
cells is called the Jak-STAT pathway [10]. Jak-STAT signaling
activates a large number of antiviral genes that are normally
quiescent or present at low levels.
Interferon gamma (IFN-c) is a type II interferon, which binds to
a separate receptor consisting of two proteins called IFNGR1 and
IFNGR2 [11]. The two kinases that signal through these receptors
are called Jak1 and Jak2 tyrosine kinases. The Jak kinases
phosphorylate STAT1 protein at tyrosine 701, which then
homodimerizes through reciprocal interaction between the
phospho-tyrosine at residue 701 and the SH2 domain of another
STAT1 molecule. This phospho-STAT1 homodimer referred to
as the interferon gamma activated factor complex translocates to
the nucleus and binds to a DNA sequence called GAS element in
the upstream promoter region of IFN-c inducible genes [11]. The
STAT1 transcription factor is a critical component for both type
Type I and Type II IFN-signaling pathways [12,13].
Our understanding of HCV resistance mechanisms to interfer-
on is possible due to the development of a HCV cell culture
system. A number of laboratories have now shown that both type
I, and type II interferons inhibit HCV replication in cell culture
models [14–17]. There have been a number of reviews where IFN
resistance mechanisms have been predicted to be related to several
viral and host related factors [18–20]. To study the role of host
cellular factors in the mechanisms of resistance, we have developed
resistant stable HCV replicon cells lines for HCV 1b and HCV 2a
viruses by prolonged treatment with interferon alpha [21–22]. We
found that replication of HCV RNA in these cells is totally
resistant to IFN-a due to Jak-STAT signaling defects. We have
characterized the role of virus and host cellular factor contribu-
tions that are responsible for IFN-a resistance in the replicon cell
line. We showed that viral factors are not involved in the resistant
phenotypes since these cells continue to display defective Jak-
STAT signaling even after the elimination of HCV. We showed
that due to Jak-STAT signaling defects, the phosphorylation and
nuclear translocation of STAT1 and STAT2 proteins are blocked
in the IFN-a resistant cell line.
IFN-c is also important in the innate antiviral immune response
against hepatitis C. IFN- c therapy has not been successful in the
treatment of chronic HCV infections that are resistant to IFN-a.
The rationale for this study is two fold. Since IFN-c has been
shown to inhibit HCV replication effectively in cell culture first we
have asked the question whether or not IFN-c could inhibit HCV
replication in replicon cells that are resistant to IFN-a. Second, we
examined whether STAT1 signaling of the host cell could be
genetically engineered to improve interferon sensitivity and to
overcome resistance in the HCV cell culture model. We found that
cells those are resistant to IFN-a survived IFN-c treatment and
formed resistant cell colonies. IFN-c resistant cell colonies were
picked and stable replicon cell lines were developed. In this study,
a recombinant STAT1 molecule with a double cysteine-substitu-
tion in the SH2 domain called STAT1-CC was utilized to activate
the GAS-promoter in the IFN-c resistant replicon cells. Transient
transfection of the STAT1-CC plasmid construct into IFN-
resistant replicon cell line inhibited HCV replication and showed
enhanced surface expression of HLA-1 in an IFN-c dependent
manner. Results of our study suggest that the engineered STAT1-
CC has strong antiviral activity in liver cells that are resistant to
IFN-a and IFN-c. We believe that liver targeted delivery of
STAT1-CC can be developed as second line treatment for patients
with defective Jak-STAT signaling. STAT1-CC may be able to
overcome HCV resistance to IFN and enhance the immune
clearance of infected hepatocytes due to high level surface HLA-1
expression.
Materials and Methods
Development of IFN-c Resistant Huh-7 Cell lines
Interferon resistant replicon cells were generated in our
laboratory by a prolonged treatment of low inducer replicon cell
lines (Con-15, Con-17, and Con-24) with IFN-a as described
previously [21]. A cured Huh-7 cell line with a defective Jak-
STAT pathway (R-Huh-7) was prepared from an IFN-aresistant
replicon cell line (R-24/1) after repeated treatment with
cyclosporine-A (1 mg/ml) as described previously [21]. Interferon
sensitive cured Huh-7 cells (S-Huh-7) were prepared using the 5-
15 replicon cell line after treatment with IFN-a. Interferon
sensitive and interferon resistant phenotypes in the cured S-Huh-7
and R-Huh-7 cells were examined by measuring their ability to
activate an ISRE-luciferase promoter in the presence of exogenous
IFN-a (Schering, Kenilworth, NJ). The expression of functional
Jak-STAT signaling proteins in these cells after IFN-a treatment
was examined by western blot analysis of phospho STAT1, and
phospho STAT2. All the resistant cell lines displayed defects in the
phosphorylation of STAT1, and STAT2 proteins, whereas the S-
Huh-7 clone showed high-level phosphorylation of STAT1, and
STAT2 proteins within 30 minutes of IFN-a treatment. All Huh-7
cell lines were maintained in Dulbecco’s modified Eagle’s medium
supplemented with 2 mM l-glutamine, nonessential amino acids,
100 U/ml of penicillin, 100 mg/ml of streptomycin and 5% fetal
bovine serum. IFN-a resistant HCV 1b replicon cell lines were first
tested for their ability to activate GAS promoter using GAS-
luciferase reporter plasmid obtained from Washington University
[23]. Replicon cell lines that showed low activation of the GAS
promoter, following IFN-c treatment were selected by culturing in
the presence of 1000 IU/ml IFN-c (PeproTech Inc. Rocky Hill,
NJ) for more than four months. The eight IFN-c resistant replicon
cells were then named GR15-1, GR15-2, GR15-3, GR17-1,
GR17-2, GR17-3, GR24-1, and GR24-2. Following the IFN-c
selection, the cells were maintained in Dulbecco’s modified Eagle’s
medium supplemented with 2 mM l-glutamine, nonessential
amino acids, 100 U/ml of penicillin, 100 mg/ml of streptomycin,
5% fetal bovine serum and 1 mg/ml of G418 for one month. The
IFN-c sensitive replicon cell line was called S9-13. The IFN-c
resistant nature of the cells was then confirmed by the following
methods.
Conformation of IFN-c Resistance
Analysis of STAT1 dependent gene expression. The first
confirmation step involved the transfection of eight IFN-c resistant
and one sensitive cell line with a GAS- Luciferase reporter
construct. All plasmid transfections were performed with
FuGENE-6 transfection reagent (Roche Diagnostic Corporation,
Indianapolis, IN) according to the manufacturer’s instructions.
STAT1-CC and HCV
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was 3 mL of Fugene-6 transfection reagent to 1 mg of plasmid
DNA. One mg of pGAS-Luc plasmid and 0.5 mg of a renilla
luciferase plasmid control was transfected by FuGENE-6 to the
sensitive and resistant cells in a 24 well plate according to the
manufacturer’s specifications. 1000 IU/ml of IFN-c (PeproTech
Inc. Rocky Hill, NJ) was then added at the time of transfection to
the appropriate groups. All experiments were performed in
triplicate. At 24 hours post-transfection the media was aspirated
and 100 mLo f1 6 reporter lysis buffer (Promega Corporation,
Madison, WI) was added to each well and incubated at 37uC for
ten minutes. The lysates were then centrifuged at 12,000 rpm for
five minutes, and the supernatant was transferred to a new set of
tubes. Twenty mg of cell lysate supernatant was added to 100 mLo f
Firefly-Luciferase assay reagent (Promega Corporation, Madison,
WI) and luciferase activity was measured by integrating the total
light emission over ten seconds with a luminometer (Luman
LB9507, EG&G Bethold, Berlin, Germany).
Ribonuclease Protection Assay for Negative Strand HCV-
RNA. The IFN-c resistance of the two cell lines with the lowest
GAS induction following IFN-c treatment from the previous
experiment was then evaluated by the ribonuclease protection
assay (RPA). The resistant cell lines GR15-3 and GR17-1 were then
plated into two 100 mm plates. At approximately 50% confluence
1000 IU/ml of IFN-c (PeproTech Inc. Rocky Hill, NJ) was added
to one plate from each cell line. At 72 hours after interferon
addition the total RNA was isolated via the GITC method. 20 mgo f
total RNA was added to 1610
6 cpm of a sense probe targeting the
highly conserved 59 untranslated region of HCV genotype 1b and
incubated at 42uC overnight. The next morning the mixture was
treated with RNase A/T1 (1:200) at 37uC for one hour. This
digestion was then terminated by the addition of 2.5 mL of SDS and
10 mL of proteinase K. The digested reaction mixture was extracted
with phenol/chloroform, precipitated and analyzed by gel
electrophoresis in a 6% denaturing TBE-Urea gel (Invitrogen,
Carlsbad, CA). The gel was then dried and exposed on X-Ray film
(Kodak Biomax-XAR, Rochester, NY).
Immunocytochemical staining. The GR17-1 cells were
seeded at a density of 1610
5 in a 12 well plate. The next day the
cells were treated with or without 1000 IU/ml IFN-c. At 72 hours
following IFN-c treatment the replicon cells were mounted onto a
glass slide via the cytospin method. The cells were then washed
twice with PBS pH 7.4 for five minutes. After air-drying, the cells
were fixed in chilled acetone for five minutes. Next, cells were
permeabilized by treatment with 0.05% saponin for ten minutes at
room temperature. Blocking was then performed utilizing five
percent of normal goat serum (Sigma Chemical Company, St.
Louis, MO) diluted in DMEM containing 5% FBS for 30 minutes
at room temperature. Endogenous biotin was then blocked
according to the manufacturer’s instructions using the Avidin/
Biotin blocking kit (Vector Laboratories, Burlingame, CA). The
cells were then incubated with monoclonal anti-NS3 antibody
(Vector Laboratories, Burlingame, CA) at a 1:50 dilution for two
hours at room temperature. Following the primary antibody
incubation, the cells were washed three times in PBS and
incubated with an anti-mouse biotin conjugated antibody
(Vector Laboratories, Burlingame, CA) at a 1:1000 dilution for
one hour at room temperature. Following the secondary antibody
incubation, the cells were incubated for 30 minutes with Elite
avidin-biotin peroxidase complex (Vector Labs, CA). Next, the
cells were treated with diaminobenzidine (DAB) chromogen (Dako
Cytomation, Carpinteria, CA) for five minutes. The slides were
then counterstained with hematoxylin for one minute, dehydrated,
mounted and observed by light microscopy.
HLA-1 Surface Expression in Sensitive and Resistant
Cells. Resistant (GR17-1) and sensitive (S9-13) replicon cells
were seeded at a density of 1610
5 in a six well plate. 24 hours later
the cells were transfected according to the previously described
method. At 48 hours post- transfection the cells were suspended in
100 mL of phosphate buffered saline (PBS) and 20 mLo f
phycoerythrin conjugated mouse anti-human HLA-A,B,C
[HLA-1(Human Leukocyte Antigen-1)] (Pharmingen, San Jose,
CA) and incubated for 15 minutes at 4uC. Following the
incubation, the cells were re-suspended in 500 mL of PBS, and
analyzed by a BD LSR-II flow cytometer (Becton-Dickinson,
Franklin Lakes, NJ) using BD FACS Diva software.
Plasmid Constructs and Transfection. Three different
STAT1 plasmid constructs were used in a transient transfection
assay to study GAS promoter activation in the IFN-c resistant cells.
The first plasmid called the pRC-CMV-STAT1 contains the full-
length STAT1 protein under the control of a CMV promoter. The
second plasmid, pRC-CMV-STAT1-CC contains the full-length
STAT1 coding sequences with Ala-656 to Cys-656 and Asn-658 to
Cys-658 substitutions. The third plasmid, pRC-CMV-STAT1-CC-
Y701F contains a mutation with Y701F substitution used as control
for phosphorylation at the amino acid 701 positions. Three different
STAT3 plasmidconstructs werealsoused ascontrol to determine the
specificity of STAT1 signaling in the transfected cells. STAT3
contains the full-length wild type STAT3 protein also under the
control of a CMV promoter. The STAT3-CC construct contains
double cysteine-substituted residues in the SH2Domain of STAT3 at
residues 661 and 663. The STAT3-CC-Y705F also contains the
double cysteine substituted residues plus a phenylalanine substitution
at residue 705. All six plasmids were obtained as a gift from the
laboratory of Dr. David A. Frank (Dana-Farber Cancer Institute,
Boston, MA) [24]. To study the role of STAT1-CC nuclear
translocation we have used full-length STAT1-GFP clone (Addgene
Inc, Cambridge, MA). The plasmids pSTAT1-CC-GFP (pCAGG
STAT1-CC-GFP) and pGAS-luciferase plasmids were provided by
Michael J Holtzman laboratory at Washington University School of
Medicine, St. Louis, Missouri [23]. The pRL-Renila luciferase
plasmid was obtained from Promega (Promega Corp, Madison, WI).
Analysis of STAT1 Phosphorylation by Co-immunopre-
cipitation. The tyrosine residue 701-phosphorylation status of the
GFPconstructswas analyzed in resistantandsensitivecelllinesbyco-
immunoprecipitation. The cells were transfected via FuGENE-6
transfection reagent in a 10-cm plate at approximately 50%
confluence with ten mg of each of the GFP tagged plasmids. At
72 hours post-transfection, the cells were treated with or without
IFN-c. Forty-five minutes after the addition of interferon the cells
werewashedtwicewithicecoldPBS.Thecellswerethenlysedbythe
addition of 500 mL RIPA buffer with proteinase and phosphatase
inhibitors (16 PBS, 1% NP-40, 0.5% Deoxycholate, 0.1% SDS,
50 mg/ml PMSF, 5 mg/ml aprotinin, 5 mg/ml leupeptin, 1 mg/ml
pepstatin). The cell lysate was then sonicated at max energy for three
pulses of five seconds each. The lysates were then centrifuged at
12,000 rpm for five minutes and the supernatant was transferred to a
new tube. 500 mg of total protein was used for each Co-IP reaction
with the final volume adjusted to 1 mg/ml with the addition of
deionized water. Four mg of GFP primary antibody (Santa Cruz
Biotechnology, Santa Cruz, CA) was added to each Co-IP reaction
and rotated at 4uC overnight. The next morning 40 mlo fP r o t e i nA /
G PLUS-Agarose (Santa Cruz Biotechnology, Santa Cruz, CA) was
added to each sample and rotated at 4uC for three hours. The
samples were then centrifuged at 3000 rpm for one minute at 4uC
and the supernatants were discarded. The samples were then washed
with 500 ml RIPA buffer for ten minutes at 4uC and centrifuged at
3000 rpm for one minute for a total of three cycles. The supernatant
STAT1-CC and HCV
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buffer. Next, samples were then boiled for five minutes centrifuged at
12,000 rpm for five minutes and the supernatant was transferred to a
new tube. 7.5 mlo f4 6 NuPAGE LDS sample buffer (Invitrogen,
Carlsbad, CA) and 3 mlo ft h e1 0 6NuPAGE sample reducing agent
(Invitrogen, Carlsbad, CA) were then added to each sample and
heated at 70uC for 10 minutes. The samples were then loaded into a
NuPAGE Novex 4-12% Bis-Tris gel 1.0 mm with 12 wells
(Invitrogen, Carlsbad, CA). The proteins were then transferred to a
Hybond-ECL nitrocellulose membrane (Amersham Biosciences,
Pittsburgh, PA). Following the gel transfer, the membrane was
stained with five times dilute Poncheau’s reagent for ten minutes and
thoroughly washed with deionized water until the pink bands clearly
appeared.
Western blot analysis. The membrane was blocked in 10 ml
of filtered blocking solution [PBS, 0.05% Tween 20, 5% Non fat
dried milk, NFDM] for 1–2 hours with gentle shaking at 4uC. Next,
membrane was washed with 15 ml of wash buffer (PBS, 0.05%
Tween 20) twice for five minutes each. The phospho-STAT1
primary antibody (Cell Signaling Technology, Danvers, MA) was
diluted (1:1000) in blocking reagent, (0.1% Tris buffered saline
tween 20, and 5% NFDM) added to the membrane, and incubated
at 4uC overnight with gentle shaking. The next day the membrane
waswashed with 15 mlofwashbuffer(PBS,0.05%Tween 20) three
times for five minutes each. The anti-Rabbit IgG HRP labeled
secondary antibody (Cell Signaling Technology, Danvers, MA) was
diluted (1:2000) in blocking reagent (0.1% Tris buffered saline
tween 20 and 5% NFDM), added to the membrane and incubated
at 4uC for two hours with gentle shaking. The membrane was again
washed with 15 ml of wash buffer (PBS, 0.05% Tween 20) three
times for five minutes each. ECL detection reagent (GE Healthcare
Life Sciences, Piscataway, NJ) was then added to the membrane
according to the manufacturer’s instructions. The membrane was
finally exposed on chemiluminescence film (GE Healthcare Life
Sciences, Piscataway, NJ) for 30 seconds.
Nuclear Translocation Assay. Cured resistant (GR17-1)
andcured sensitivelineswereplatedina twowellLab-Tek chamber
slide (Electron Microcopy Sciences, Hatfield, PA) at a density of
5610
4 cells per ml. Twenty four hours later the cells were
transfected with 1 mg of the respective STAT1-GFP plasmid. At
24 hours post- transfection To-Pro3 nuclear marker (Invitrogen,
Molecular Probes, Oregon) was added to the samples at 1 mg/ml,
and incubated for five minutes in PBS. IFN-c (1000 IU/ml) was
then added to the appropriate groups. Confocal microscopy was
performed using a Leica TCS SP2 confocal microscope equipped
with three lasers (Leica Microsystems, Exton, PA). Optical slices
were collected at 5126512 pixel resolution. NIH Image version
1.62 and Adobe Photoshop version 7.0 were used to assign correct
colors of channels collected, including the Green Fluorescent
Protein (green), To-Pro3 633 (far red), and the differential
interference contrast image (DIC) (gray scale). Final magnification
is indicated in the figures with a bar.
Infectivity Assay. Stable cell lines were created for STAT1
and STAT1-CC in the IFN-c resistant cured cell line (GR17-1)
and the IFN-c sensitive cured cell line (S5-15) by treatment with
cyclosporine as previously described [21]. The effect of the
engineered STAT1 constructs on the production of full length
infectious HCV were examined by a multicycle infectivity assay as
previously described [22]. Interferon sensitive and resistant stable
Huh-7 cell lines containing STAT1 and STAT1-CC were infected
with full-length JFH1 HCV at a multiplicity of infection of one.
IFN-c (1000 IU/ml) was added to the appropriate groups at the
time of infection. After 96 hours of infection, total RNA from the
infected cells was isolated by the GITC method [21]. Two
micrograms of total RNA was then reverse-transcribed, and
quantified by RT-qPCR utilizing the following primer sets and
probe Sense: 59-TCTTCACGCAGAAAGCGTCTA-39, Anti-
Sense 59-CGGTTCCGCAGACCACTATG-39, Taq-man FAM
labeled probe 59-/56-FAM/TGAGTGTCG/ZEN/TGCAGC-
CTCCAGGA/3IABkFQ/-39. A CFX96 Real Time instrument
with CFX manager software (Bio Rad, Hercules, CA) was used to
amplify and analyze the samples.
MTT Assay. The toxicity of each STAT1 construct was
evaluated by the MTT assay. 2610
4 IFN-c resistant cells were
plated in a 24 well plate. After 24 hours, the media was replaced with
500 mL of DMEM supplemented with 2% FBS. One hour after the
media change each well was transfected with 1 mg of STAT1 plasmid,
3 mL of FuGENE-6 transfection reagent (Roche Diagnostics
Corporation, Indianapolis, IN), and 30 mL of serum free media
according to the manufacturer’s recommendations. The experimental
controls included cells only, and cells plus FuGENE-6 transfection
reagent only. At ten hours post-transfection, 500 mLD M E M
containing 10% FBS was added to each well. The MTT solution
(Sigma-Aldrich, St. Louis, MO) was then prepared by dissolving 5 mg
of the powder (Sigma catalogue #M5655) in 1 mL of distilled water,
and filtered through a 0.2 mm filter and stored at 2–8uCu n t i lu s e .A t
48 hours post-transfection 100 mL of the MTT solution was added to
the media in each well, including an additional control well containing
only 1 mL of media without cells. The cells were then incubated at
37uC for three hours. The media was aspirated and 1 ml of acidic
isopropanol (0.1N HCL in absolute isopropanol) was added to each
well including the cell free media only control well. The absorbance of
each sample was then measured at 570 nm utilizing a
spectrophotometer. The percent viability was then calculated
utilizing the formula (value of sample/mean value of control cells
only).
Results
Development of IFN-c resistant HCV replicon cell line
IFN-a is a key component of the standard treatment for chronic
HCV infection. However, the development of resistance to
interferon therapy is a major obstacle in curing chronic HCV
infection. Previously we have developed IFN-a resistant cell lines
in an attempt to understand the contribution of viral and host
cellular factors in the mechanisms of IFN resistance. Subsequently
we have utilized the IFN-a resistant cell lines as model systems to
develop alternative strategies to overcome IFN resistance mech-
anisms. These cell lines contain defective Jak-STAT signaling due
to the expression of a truncated IFNAR1 that leads to impaired
STAT1 and STAT2 phosphorylation and an ineffective antiviral
response. IFN-c is also important in the innate antiviral immune
response against hepatitis C. IFN-c therapy has been unsuccessful
in the treatment of chronic HCV infections that are resistant to
IFN-a [25–27]. The precise molecular mechanism underlying this
phenomenon is unclear. Since IFN-c has been shown to inhibit
HCV replication effectively in cell culture first we examined if
IFN-c could inhibit HCV replication in IFN-a resistant replicon
cells. It was found that all IFN-a resistant replicon cell lines
survived the IFN-c treatment and formed resistant cell colonies.
These experiments suggested that the cells that were IFN-a
resistant also remained resistant to IFN-c treatment. The activity
of the GAS promoter in these stable replicon cell lines was
determined in a transient transfection assay. The results presented
in Fig. 1A, suggest that there was significant variation in GAS
promoter activation between the sensitive and resistant replicon
cells. We also found substantial variation of GAS promoter
activation among the nine different HCV 1b replicon cell lines.
STAT1-CC and HCV
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3 and GR17-1 cells was the lowest. The levels of HCV RNA and
protein were examined after IFN-c treatment to provide a more
detailed analysis of the resistant nature of the two cell lines. The
GR15-3 and GR17-1 replicon cell lines were treated with IFN-c
for 72 hours and total RNA was probed for HCV RNA levels by
RPA. The results presented in Fig. 1B, suggest that both of these
cell lines displayed no reduction in viral RNA following IFN-c
treatment. Immunocytochemical staining for HCV NS3 protein in
GR17-1 cells treated with IFN-c was used as the final confirmation
of IFN-c resistance. Treatment with IFN-c had no effect upon
viral protein levels thus confirming the resistance of the GR17-1
line (Fig.1C). As a result, the GR17-1 cell line was used as the
model system for IFN-c resistance. IFN-c signaling is mediated by
Jak1 and Jak2 tyrosine kinases. IFN-c binding to the receptor
(IFNGR) phosphorylate STAT1 molecule which then subsequent-
ly homodimerizes to form the gamma activated factor (GAF)
complex. This factor then binds to GAS elements in IFN-c
inducible promoters. Some of the GAF is also formed following
IFN-a stimulation, which explains the ability of both types of IFNs
to activate genes with GAS sites and their partially overlapping
functions [23]. The phosphorylation of Jak1, Jak2 and STAT1 was
examined in the sensitive and resistant line by western blot
analysis. The results shown in Fig. 2 suggest a lack of
phosphorylation of Jak1, Jak2 and STAT1 in the resistant cell
lines compared to the 9-13 sensitive cell line. These results support
our conclusion that IFN-c resistant replicon cells have defective
STAT1 phosphorylation and nuclear translocation.
STAT1-CC activates GAS promoter in resistant HCV
replicon cells in an IFN-c dependent manner
We tried to determine whether we could overcome the defective
Jak-STAT signaling and interferon resistance in HCV cell culture
by intracellular expression of a modified STAT1 protein as
described previously [23-24]. We generated a mutant plasmid
clone (STAT1-CC) with double-cysteine substitutions in the C-
terminal domains of the STAT1 molecule at the amino acids 656
and 658 as illustrated in Fig. 3A-i. This mutation was expected to
allow for spontaneous disulfide bonding and STAT1 homodimer-
ization as described for STAT3 [25]. To determine whether the
presence of cysteine residues is sufficient to allow for functional
activation in the absence of tyrosine phosphorylation, we used a
STAT1-CC mutant containing an Y701F substitution. The
STAT1 molecule expressed from this construct cannot be
phosphorylated at residue 701; therefore this control will
determine whether phospho-tyrosine 701 is essential for STAT1-
Figure 1. Confirmation of the IFN-c resistance of HCV 1b replicon cell lines. (A) The GAS-luciferase activity in the sensitive and resistant
replicons. One sensitive and eight resistant cell lines were seeded in 24 well plates. The next day the cells were transfected with 1 mg of GAS-firefly
luciferase and 500 ng of renilla luciferase plasmid using the FuGENE 6 transfection reagent and then treated with or without IFN-c (1000 IU/ml). The
cells were then assayed for GAS promoter induction 24 hours after the addition of IFN-c. The GAS firefly luciferase value of each well was normalized
with a renilla luciferase control. The values were expressed as fold change in GAS luciferase expression after IFN-c addition. Error bars represent
Standard Error of the Mean (SEM) from six independent experiments. (B) RPA for negative strand RNA showing the replication of HCV in the resistant
replicon with and without IFN-c after 72 hours. Two IFN-c resistant cell lines were treated with or without IFN-c (1000 IU/ml). At 72 hours post-
transfection total RNA was isolated by the GITC method and subjected to RPA for detection of the positive sense strand of the HCV genotype 1b
59UTR. (C) Immunostaining of NS3 proteins of HCV using GR17-1 cells treated or not treated with IFN-c for 72 hours. The IFN-c resistant GR17-1 cells
were treated with or without IFN-c. At 72 hours the cells were mounted onto a glass slide, stained for HCV NS3 (DAB), and counterstained with
hematoxylin.
doi:10.1371/journal.pone.0013117.g001
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STAT3 molecules as a control as shown in Fig. 3A–ii,t o
determine if the defective Jak-STAT signaling in the resistant
replicon cell line can be overcome specifically by the modified
STAT1 protein. To assess if the disulfide substituted STAT1
construct efficiently translocates to the nucleus, we used three
types of STAT1 constructs containing c-terminal green fluores-
cence protein (GFP) fusions (Fig. 3A–iii). The STAT1 GFP fusion
constructs were also prepared to study their ability for nuclear
translocation in the GR17-1 resistant cell line under a fluorescence
microscope. In the first step, we examined whether intracellular
expression of STAT1-CC after plasmid DNA transfection could
improve the STAT1 signaling in the IFN-c resistant replicon cells.
GR17-1 resistant replicon cells were transfected with the wild type
STAT1, STAT1-CC and STAT1-CC (Y701F) mutant plasmid
along with GAS-luciferase reporter (Fig. 3B–D). After 24 hours,
the activity of the GAS reporter in the cell lysates with or without
treatment with IFN-a and IFN-c was determined by the luciferase
assay. We found that that intracellular expression of STAT1,
STAT1-CC or STAT1-Y701F did not induce GAS promoter in
the resistant cells. We then examined activation of the GAS
promoter in the transfected cells by the addition of either IFN-c or
IFN-a. The results shown in Fig. 3B suggest that GAS promoter
activity was substantially increased in the cells after treatment with
IFN-c for STAT1-CC. IFN-a did not increase GAS promoter
activity of cells transfected with STAT1-CC suggesting that the
activation is IFN-c dependent. The activation of the GAS-
luciferase in the resistant cells is dependent upon tyrosine
phosphorylation at residue 701 since no GAS induction activation
was observed in cells transfected with the STAT1-CC-Y701F
construct. In the second step of our analysis, we asked the question
whether the activation of the GAS promoter in the transfected
GR-17 resistant cells is specific to the modified STAT1-CC
molecule. For this purpose, resistant cells were transfected with
three sets of STAT1 constructs (STAT1, STAT1-CC, STAT1-
CC-Y701F) and three sets of STAT3 constructs (STAT3, STAT3-
CC, STAT3-CC-Y705F) and their activation after IFN-c
treatment was examined. The results presented in Fig. 3C suggest
that only the engineered STAT1CC could activate GAS-luciferase
activity in the resistant cells. The modified STAT3-CC construct
did not induce GAS-luciferase activity in resistant Huh-7 cells
following IFN-c treatment. In these experiments we found that the
STAT1-CC molecule was able to activate GAS promoter more
effectively than the wild type STAT1 protein, but that the
activation is IFN-c treatment dependent. In the third set of
experiments, we examined whether the activation of the GAS-
promoter in the transfected cells is concentration dependent. The
results presented in Fig. 4D suggest that the activation of GAS-
luciferase is concentration dependent. All of the STAT1 constructs
exhibited a dose dependent increase in RLU over the experimen-
tal dose range. In the fourth set of experiments we evaluated the
kinetics of GAS promoter induction between STAT1-CC and wild
type STAT1 at various time points up to 48 hours post-
transfection. No noticeable differences were observed between
the two groups until the 24 hour time point when the STAT1-CC
transfected cells showed a marked increase in GAS promoter
induction versus wild type STAT1. In the STAT1-CC transfected
cells, an interesting phenomenon occurred at the 48 hours time
point when GAS expression had increased from the 24 hour time
point whereas the STAT1 cells exhibited lower GAS luciferase
expression than the 24 hour time point (Fig. 3E). Furthermore,
the difference in GAS expression between these two groups
reached statistical significance (p,0.05, Students t-test) at the 48-
hour time point.
Intracellular expression of STAT1-CC significantly up
regulates HLA expression in interferon-c resistant cells
To verify the results of luciferase based promoter activation,
we examined the effect of STAT1-CC expression in the
resistant cell line on the constitutive expression of a known
IFN-c responsive gene, HLA-1 [28–30].The expression ofHLA
class I surface expression was analyzed by flow cytometry in the
Figure 2. Western blot analysis showing low level p-Jak1 and p-Jak 2 expression in the GR17-1 cells and no STAT1 phosphorylation
following IFN-c treatment. Resistant and sensitive cell lines were treated with and without IFN-c. Thirty minutes after IFN-c addition, protein
lysates were obtained and quantified. Ten micrograms of protein lysates were subjected to western blot analysis using phospho specific antibodies.
Phosphorylation of Jak1, Jak2 and Stat1 was observed in sensitive Huh-7 (S9-13) cells after treatment with IFN-c. These proteins were not detected in
GR17-1 resistant replicon cell lines after IFN-c treatment.
doi:10.1371/journal.pone.0013117.g002
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treatment. The results shown inFig.4 show that HLA-1 surface
expression levels remained constant in the resistant cell line
after IFN-c treatment, whereas surface expression of HLA-1
was up-regulated in the sensitive cell line following IFN-c
treatment. Since immune surveillance of the surface-expressed
HLA associated peptide complex and presentation to cytotoxic
T cells is an important mechanism of viral clearance, we
examined the ability of the STAT1-CC constructs to upregulate
HLA-1 surface expression in IFN-c resistant cells. The resistant
replicon cell line GR17-1 was transfected separately with either
wild type STAT1, STAT1-CC or STAT1-CC-Y-F plasmid.
After 72 hours, expression of HLA-1 in the transfected cells was
examined after staining with a monoclonal antibody specific to
human HLA-1 antigen. The flow analysis results in Fig. 4 A
and B. show that STAT1-CC plus IFN-c significantly
upregulated HLA-1 expression compared to resistant cells
alone (Student’s t-test p,0.05). The surface expression levels of
HLA-1 remained unchanged for the remaining experimental
groups.
Figure 3. IFN-c dependent activation of GAS promoter by the STAT1-CC molecule in the resistant (GR17-1) replicon. (A) Summary of
different modified STAT plasmid constructs used in this project. (i) Shows pRC-CMV plasmid containing human full-length wild type STAT1 cDNA,
STAT1-CC containing two cysteine substitutions in the SH2 Domain of STAT1 at residues 656 and 658 and STAT1-CC-Y701F also contained the double
cysteine substituted residues plus a phenylalanine substitution at residue 701. (ii) Shows the pRC-CMV expression plasmid containing the full-length
human wild type STAT3 cDNA. STAT3-CC double cysteine substituted residues in the SH2 Domain of STAT3 at residues 661 and 663, STAT3-CC-Y705F
also contained the double cysteine substituted residues plus a phenylalanine substitution at residue 705. (iii) STAT1 constructs with a C-terminal GFP
fusion, STAT1-CC-GFP and STAT1-CC-Y701F–GFP plasmid. (iv) Firefly luciferase reporter construct driven by GAS promoters. (B) Show the activation
of GAS promoter in resistant cell line transfected with Stat1, Stat1CC and Stat1CC Y-F plasmids. IFN-c resistant cells (GR17-1) were transiently co-
transfected with a GAS-firefly luciferase reporter, the indicated STAT1 construct and a control plasmid expressing renilla luciferase. Firefly luciferase
activity was normalized with the transfection control renilla luciferase. Each bar represents the fold increase in GAS promoter expression activitya t
24 hours after the addition of IFN. The error bars represent the SEM from six independent experiments. GAS-firefly luciferase activity increased in
response to IFN-c treatment. IFN-a treatment did not induce the GAS promoter. (C) Shows that the activation of the GAS promoter is specific to
STAT1-CC. Interferon resistant cells (GR17-1) were transiently co-transfected with a GAS luciferase reporter and one microgram of each of the
constructs using the FuGENE 6 reagent. Values were normalized with renilla luciferase and presented as the fold increase in GAS promoter induction
between IFN naı ¨ve and IFN-c treated cells 24 hours post-transfection are shown. (D) Dose dependent activation of the GAS promoter by STAT1-CC
molecules in the GR17-1 cell line. The STAT1 constructs induce the GAS promoter in a dose dependent manner. Different concentrations (0.5, 1, and
2 mg) of the respective STAT1 plasmid and 0.5 mg of GAS-luciferase were co-transfected to GR17-1 cells by FuGENE 6 reagent and then treated with
1000 IU of IFN-c. At 24 hours, the luciferase activity was measured and normalized with renilla luciferase as a transfection control. Values represent
normalized luciferase expression (RLU) from three experiments. (E) Prolonged GAS-luciferase activity in the resistant cells transfected with STAT1-CC
compared to wild type STAT1. At the indicated time points, RLU activity was measured, normalized with renilla luciferase, and represented as fold
change in GAS induction after IFN-c addition.
doi:10.1371/journal.pone.0013117.g003
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resistant cells
In the previous experiments we found that intracellular
expression of STAT1-CC in the GR17-1 cells after plasmid
DNA transfection is not sufficient to cause GAS-luciferase
activation. The activation of GAS-luciferase in the STAT1-CC
transfected cells is dependent on IFN-c treatment. Therefore, we
examined the phosphorylation of the STAT1-CC molecule in the
transfected cells by co-immunoprecipitation experiments. In these
experiments we used both wild type STAT1 and mutant STAT1-
CC constructs with GFP tags to monitor the extent of
phosphorylation. A sensitive Huh-7 replicon (S9-13) and resistant
replicon (GR17-1) cell line was transfected with STAT1-GFP,
STAT1-CC-GFP or STAT1-CC-Y701F-GFP plasmid. The
phosphorylation of each molecule was then examined by co-
immunoprecipitation with a GFP antibody followed by a western
blot using an antibody against p-STAT1. The results presented in
Fig. 5 suggest that the STAT1-CC molecule was phosphorylated
in GR17-1 cells as evidenced by the detection of a distinct band in
the immunoblot analysis of STAT1-CC transfected cells after IFN-
c treatment only. Neither the wild type STAT1 nor the STAT1-
CC-Y701F construct showed any evidence of phosphorylation in
GR17-1 cells. Furthermore, it was found that STAT1-CC was
phosphorylated at a very high level in the sensitive 9–13 cells with
or without IFN-c treatment (Fig. 5). In the sensitive cells, STAT1-
GFP was also phosphorylated after IFN-c treatment. These
findings are consistent with the results of the GAS-luciferase
promoter assay induced by the wild type and mutant STAT1
constructs in the resistant cell line.
Nuclear translocation of STAT1-CC-GFP in the resistant
cells is dependent on tyrosine phosphorylation
We examined whether the low level of phosphorylation of the
STAT1-CC construct in the resistant cells was responsible for
nuclear translocation of STAT1-CC-GFP molecule in the resistant
cell. Both S9-13 and GR17-1 cells were transfected with STAT1-
GFP, STAT1-CC-GFP or STAT1CC-Y701F-GFP constructs and
their nuclear translocation was examined under a confocal
microscope with or without IFN-c treatment. The results of these
experiments are shown in Fig. 6. In the sensitive cell line, the
STAT1-GFP chimera protein was expressed primarily in the
cytoplasm and subsequently translocated to the nucleus 30
minutes following IFN-c treatment. The STAT1-GFP was unable
to localize to the nucleus following IFN-c treatment in the resistant
cell line. In contrast, the STAT1-CC-GFP construct efficiently
localized to the nucleus within 30 minutes of IFN-c addition in
both sensitive and resistant cell lines. There were no differences in
the nuclear translocation of the STAT1-CC-GFP molecule in the
sensitive and resistant cells with the addition of IFN-c. The
translocation of the STAT1-CC-GFP chimera in the sensitive and
resistant cell was phosphorylation dependent since we did not
observe nuclear translocation of STAT1-CC-GFP protein with
Y701F substitution.
Enhanced viral clearance in cell culture by intracellular
expression of modified STAT1-CC molecule
The modified STAT1-CC molecule is able to activate the GAS
promoter more effectively than the wild type STAT1 molecule in
the resistant cells. Therefore, we investigated whether intracellular
Figure 4. Intracellular STAT1-CC upregulates HLA class I surface expression in IFN-c resistant (GR17-1) cells. GR17-1 cells were
transfected with STAT1, STAT1-CC or STAT1-CC-Y701F plasmid using FuGENE 6 reagent for 72 hours with or without IFN-c treatment. After 72 hours,
the cells were harvested and stained with a phycoerythrin-conjugated anti-human HLA antibody. Surface HLA-1 expression was then quantified by
flow cytometry. (A) Each histogram is representative of six independent experiments. The red cell population in each histogram represents IFN-c
naı ¨ve cells and the blue cell population represents IFN-c treated cells. (B) Mean fluorescence intensity of six independent experiments per group.
Values represent fold increase in HLA1 expression after the addition of IFN-c. Mock represents GR17-1 cells without plasmid transfection. Asterisk (*)
denotes a significant (p,0.05) increase in HLA1 in STAT1-CC transfected cells plus IFN-c compared to mock.
doi:10.1371/journal.pone.0013117.g004
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resistance and induce an HCV antiviral response. Resistant
replicon cells were transfected with STAT1-CC expression
plasmid and then treated with IFN-c for 72 hours. The HCV
negative strand RNA level in the transfected cells was then
examined by the RPA method. The results of these experiments
shown in Fig. 7, suggest that STAT1-CC effectively abolished
HCV RNA replication in an IFN-c dependent manner. The
inhibition of HCV replication was not observed in cells transfected
with either the STAT1 construct or the STAT1-CC construct with
an Y701F substitution. GAPDH mRNA levels remained constant
in all of the samples tested suggesting that the antiviral effect was
due to the intracellular expression of STAT1-CC protein. To
verify these results, immunostaining was performed to examine
viral NS3 protein levels in the transfected resistant GR17-1 cells at
72 hours post-transfection. These results shown in Fig. 8
demonstrate potent antiviral action in the IFN-c treated,
STAT1-CC transfected culture, while the controls showed no
decrease in viral NS3 protein levels. We also examined if this
antiviral strategy can be extended to eliminate cell culture grown
full-length infectious virus in the IFN-c resistant cell line (GR17-1).
The antiviral effect of IFN-c against cell culture grown full-length
HCV was also examined using interferon sensitive Huh-7 cells.
Cured 5-15 Huh-7 cells were cultured in 6-well plates and infected
with cell culture derived full-length HCV at a MOI of one. After
72 hours of infection, the culture was treated with increasing dose
of IFN-a or IFN-c. Antiviral effect was determined after 72 hours
by measuring the HCV RNA titer by real-time RT-PCR. The
results in Fig. 9A demonstrate a dose dependent increase in
antiviral activity of IFN-c against full-length HCV. We then
examined the ability of stably expressed STAT1 or STAT1-CC
proteins in the cured GR17-1 Huh-7 cells to inhibit replication of
full-length infectious virus. The results of the infectivity assay in the
engineered STAT1 sensitive (S5-15) and resistant (GR17-1) stable
cell lines are shown in Fig. 9B. The control GR17-1 cured IFN-
cresistant cell line showed no reduction in viral RNA after the
addition of IFN-c (1000 IU/ml). The stable STAT1 expressing
GR17-1 cell line showed a modest reduction in HCV RNA with
the addition of IFN-c. In contrast, the stable STAT1-CC
expressing GR17-1 cell line showed a significant (p,0.02)
reduction in HCV RNA after the addition of IFN-c. The sensitive
STAT1-CC expressing stable cell line also showed a significant
(p,0.02) reduction in HCV RNA level after IFN-c treatment. In
order to determine if the viral clearance is due to a toxic effect of
intracellular expression of the STAT1-CC molecule, cell viability
was determined by the MTT assay. The results in Fig. 10 show
that the viability (as a percentage of control) of the STAT1
transfected resistant cells was 96.5 and the addition of IFN-c had
no significant effect on cell viability. The STAT1-CC transfected
cells exhibited intermediate cytotoxicity with 93.7% viability and
this number dropped to 86.3 percent with the addition of IFN-c.
The STAT1-CC-Y701F transfected cells exhibited the most
toxicity with 88% of cells remaining viable, and 85% of cells
remained viable after the addition of interferon. To search for an
explanation for the potent antiviral activity of STAT1-CC
molecule in the resistant replicon cells, western blot analysis was
performed of two targets, p-PKR and p-EIF2a. IFN-c treatment
induced high levels of phosphorylated PKR and phosphorylated
eIF-2 alpha in cells expressing STAT1-CC where as STAT1 and
STAT1-CC-Y701F expressing cells did not induce these targets
(Fig. 11). In summary, these results suggest that the intracellular
expression of STAT1-CC induced a potential antiviral response in
an IFN-c dependent manner that involves the activation of PKR
and eIF-2a phosphorylation.
Discussion
IFN-a is the standard treatment for chronic hepatitis C virus
infection. More than half of chronic HCV patients are unable to
clear the virus infection and develop resistance to combination
therapy. We have developed multiple resistance replicon cell lines
to understand the mechanisms of HCV resistance to IFN-a.W e
showed that defects in phosphorylation STAT1 and STAT2
proteins led to their impaired nuclear translocation and IFN-a
resistance (21–22). This study was performed to examine effect of
IFN-c treatment on the replication of HCV in IFN-a resistant
Figure 5. Comparison of spontaneous and IFN-c dependent phosphorylation of STAT1-CC molecule in sensitive (S9-13) and
resistant (GR17-1) cells. Cells were transfected with individual plasmid constructs of either STAT1-GFP, STAT1-CC-GFP, or STAT1-CC-Y701F–GFP.
IFN-c was added to the appropriate groups at 72 hours post-transfection. Thirty minutes after IFN-c addition, the protein lysates were
immunoprecipitated using an anti-GFP antibody. Immunocomplexes were detected using an antibody to phospho-STAT1 by western blot analysis.
Upper panel: Preferential phosphorylation of STAT1-CC over the STAT1 molecule in IFN-c sensitive Huh-7 cells (S9-13). IFN-c dependent
phosphorylation was seen for both wild type STAT1 molecule as well as Stat1CC molecule. Lower panel: The STAT1-CC showed low level
phosphorylation of Stat1CC in the resistant cells in IFN-c treated cells.
doi:10.1371/journal.pone.0013117.g005
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PLoS ONE | www.plosone.org 9 September 2010 | Volume 5 | Issue 9 | e13117Figure 7. RPA assay demonstrates that STAT1-CC plus IFN-c eliminates HCV negative strand RNA in resistant replicon cells. IFN-c
resistant (GR17-1) cells were transfected with the respective plasmid and treated with or without IFN-c. At 72 hours post-transfection total RNA was
isolated by the GITC method and subjected to RPA analysis for HCV negative strand RNA using a probe targeted to the highly conserved 59-UTR
region. The GAPDH mRNA was used as loading control. The nucleotide number in each blot shows the length of the protected fragment.
doi:10.1371/journal.pone.0013117.g007
Figure 6. STAT1-CC-GFP translocates to the nucleus of GR17-1 cells in an IFN-c dependent manner. IFN-sensitive (S9-13) and IFN-
resistant (GR17-1) cells were transfected with plasmid containing STAT1-GFP, STAT1-CC-GFP and STAT1-CC-Y701F-GFP. The nuclear translocation of
each STAT1-GFP construct with or without IFN-c treatment in the sensitive and resistant cells was examined under a confocal microscope. (A) Shows
high resolution picture of Stat1-GFP nuclear translocation after IFN-c treatment in the sensitive Huh-7 (S9-13) cells. The images are represented as the
superimposition of Green Fluorescent Protein (green), To-Pro3 633 (far red), and the differential interference contrast images (DIC) (gray scale).( B)
Shows the differential nuclear translocation of STAT1-GFP, STAT1-CC-GFP and STAT1-CC-Y701F-GFP protein in the sensitive (S9-13) versus resistant
Huh-7 (GR17-1) cells before and after treatment with IFN-c. Fluorescence green and red microscopic picture of the same area were taken and
superimposed using Abode Photoshop.
doi:10.1371/journal.pone.0013117.g006
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antiviral activity against HCV in cell culture but it is not very
effective in the treatment of chronic hepatitis C patients who are
non-responders to IFN-a[25]. The reason why IFN-c treatment is
not effective in the chronic HCV patients resistant to IFN-a is
unknown. Since the antiviral action of IFN-c is mediated through
separate receptors, we tested here whether IFN-c can inhibit HCV
replication in IFN-c resistant replicon cells. The results of our
study suggest that replicon cells that are resistant to IFN-aalso
develop resistant to IFN-c. Through this approach we have now
developed IFN-c resistant stable replicon cell lines. We describe
here a novel approach of how to improve the sustained virologic
response of HCV infection using IFN-c in patients who are non-
responders to IFN-a.
As a proof-of-principle, we have utilized these IFN-c resistant
cell lines to develop alternative treatment approaches to overcome
HCV resistance to IFN in cell culture. Since STAT1 is activated
by both type I and Type II IFN stimulations, we therefore
examimed whether intracellular STAT1 signaling could be
activated by intracellular expression of the modified STAT1-
CC molecule to overcome viral resistance to IFN. We showed that
intracellular expression of a STAT1-CC molecule induced GAS
promoter activity in an IFN-c dependent manner. Intracellular
expression of the engineered STAT1-CC molecule led to
phosphorylation and nuclear translocation in resistant replicon
cells in an IFN-c dependent manner. A mechanism of phospho-
STAT1 dephosphorylation has been proposed whereby the
phospho-STAT1 homodimer undergoes a molecular rearrange-
ment from a parallel to an antiparallel orientation within the
nucleus [31]. This molecular rearrangement then exposes the
tyrosine residue at position 701 to the activity of phosphatases.
Following dephosphorylation, the STAT1 molecule is exported
from the nucleus. Zhong et al [31] was able to demonstrate that
STAT1 mutants containing mutations in various STAT1
domains were resistant to tyrosine phosphatases in vitro. The
increased activity of the STAT1-CC molecule in the resistant cell
is likely as a result of a delay of dephosphorylation when
compared to wild type STAT1 [23]. Within the cell the STAT1
molecule undergoes a basal level of phosphorylation and
dephosphorylation [31]. The increased stability and delay of
dephosphorylation of the STAT1-CCm o l e c u l es h i f t st h i sb a l a n c e
of phosphorylation and dephosphorylation toward the phosphor-
ylated state. As a result, the low level kinase activity of Jak 1 and
Jak2 observed in the resistant cell line following IFN-c treatment
may be sufficient to generate pSTAT1 levels that induce the GAS
promoter. This may explain the IFN-c dependence of the
STAT1-CC molecule within the resistant cell line. We showed
that the increased stability of the STAT1-CC molecule led to
prolonged transcriptional activity that resulted in increased
antiviral and immunomodulatory activities in the interferon
resistant cell line. It was found that HCV RNA replication and
viral protein expression were effectively inhibited by intracellular
expression of the STAT1-CC molecule. Neither wild type STAT1
nor the STAT1-CC-Y701F mutant transfection resulted in a
reduction of HCV RNA levels in the resistant cell line. This
suggested that the antiviral effect is specific to the STAT1-CC
expression. We also showed that intracellular expression of
STAT1-CC has limited cellular toxicity since more than 80%
cells remained viable. Intracellular expression of SH2 modified
STAT1 protein (called STAT1-CC) improves the defective Jak-
STAT signaling and eliminates cell culture derived full-length
infectious HCV replication in an IFN-a sensitive and resistant
hepatic cell line by IFN-c. Based on the results, we propose that
liver targeted delivery of modified STAT1-CC protein can
stimulate the antiviral response as well as HLA-1 expression in
hepatocytes in an IFN-c dependent manner.
Figure 8. STAT1-CC plus IFN-c transfected resistant (GR17-1) cells display a marked reduction in HCV NS3 protein. IFN-c resistant cells
were transfected separately with the respective STAT1 plasmid and treated with or without IFN-c. At 72 hours the cells were mounted onto a glass
slide, stained for with DAB for HCV NS3 (brown), and counterstained with hematoxylin (blue). Huh7 cells without virus were used as a negative
control.
doi:10.1371/journal.pone.0013117.g008
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PLoS ONE | www.plosone.org 11 September 2010 | Volume 5 | Issue 9 | e13117Figure 9. Effect of STAT1-CC and IFN-c on cell culture grown full-length HCV. Stable sensitive (S5-15) and resistant (GR17-1) cell lines with
or without STAT1 or STAT1-CC were infected with full length HCV genotype 2a clone JFH1 virus at MOI of 1.0. After 72 hours cells were treated with
IFN-c. At 72 hours post-infection total RNA was isolated, positive strand HCV RNA level was measured by real-time RT-PCR. (A) Antiviral effect of IFN-c
and IFN-a against cell culture grown full-length HCV. (B) Demonstrate the antiviral effect of Stat1-CC expression on cell culture derived full-length
HCV RNA in sensitive and resistant cells due to IFN-c treatment. Bars are representative of three independent experiments and error bars represent
standard error of the mean. Significance was considered at values below 0.05 (p,0.05, student t-test). Asterisks (*) represent significant (p,0.02)
reductions in HCV RNA.
doi:10.1371/journal.pone.0013117.g009
Figure 10. The cytotoxicity of intracellular expression of each STAT1 molecule in the resistant cells. The GR17-1 cell line was transfected
with each of the STAT1 constructs and the cellular toxicity was performed at 48 hours post-transfection by the MTT assay. The values represent viable
cells as a percent of cells plus FuGENE-6 control. Bars represent SEM from three experiments.
doi:10.1371/journal.pone.0013117.g010
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antiviral strategy, which can be explored to overcome IFN-a
resistance, and to enhance the immune mediated clearance of virus
HCV infected cells. Numerous studies have indicated that cellular
Jak-STAT signaling initiated by type I interferon appear to be
suppressed in chronic HCV infection [32]. A number of clinical
studies including the recent HALT-C trial suggest that impaired
expression of IFNAR1 is correlated with the response to IFN-a
therapy in chronic hepatitis C. Taniguchi et al [33] indicated that
high intrahepatic mRNA levels of IFNAR1 and the ratio of IFNAR1
to IFNAR2 were significantly higher in patients having a sustained
virological response to interferon therapy. Katsumi et al [34] found
that the expression rate of IFNAR1 and IFNAR2 were significantly
higher in responders than non-responders. Fujiwara et al [35] have
conducted a study where the expression of IFNAR1 receptor and
response to interferon therapy was examined in chronic hepatitis C
patients. They found that the IFNAR2 expression level in the liver,
but not in the PBMC, is predictive of the response to IFN treatment
in chronic hepatitis C patients. Meng et al [36] also examined the
expression of interferon alpha/beta receptor in the liver of patients
with hepatitis C virus related chronic liver disease between interferon
responders and non-responders. In this study, the authors found that
the expression of the interferon receptor was higher in the IFN-
treatment responsive group than in the non-responsive group. Welzel
et al [37] analyzed the relationship between variants in the IFN-a
pathway and a sustained virologic response (SVR) among partici-
pants in the hepatitis C antiviral long-term treatment against the
cirrhosis (HALT-C) trial. They found a statistically significant
relationship between IFNAR1 expression and response to antiviral
therapy in chronic hepatitis C patients. The results of these clinical
studies are supported by a recent cell culture study conducted by Liu
et al [38] that suggested that HCV infection can lead to impaired
cellular Jak-STAT signaling by down regulation of IFNAR1. These
studies provide strong evidence on the contribution of defective
cellular Jak-STAT signaling in HCV infected hepatocytes upon the
interferon antiviral response. Additionalstudies have shown that IFN-
stimulated genes (ISG) in the liver of HCV infected patients are
expressed at higher levels pre-treatment in IFN non-responders
compared to IFN responders [39–41]. In contrast to these
observations another study showed little or no evidence of ISG
expression in the liver of chronically infected IFN non-responders
[41]. In this study the authors found that IFN-a induced STAT1
phosphorylation and nuclear translocation was stronger in the
hepatocytes of responders than in non-responders. The activation of
STAT1 in the non-responders was primarily observed in the non-
hepatic cells (Kupffer cells) [41]. In this study, we showed that
intracellular expression of SH2 modified STAT1 protein (called
STAT1-CC) improves defective Jak-STAT signaling and eliminates
HCV replication in an IFN-a sensitive and resistant hepatic cell line
in an IFN-cdependent manner. As a result, the subset of patients that
contain a functionally inactivated IFNAR1, IFNAR2 or other
variants of the Jak-STAT pathway that are adversely associated with
a sustained virological response may benefit from a liver targeted
STAT1-CC therapy. There are new reports indicating that targeted
delivery of therapeutic molecules can be achieved using apolipopro-
tein conjugated liposomes [42–43]. We propose that liver targeted
delivery of modified STAT1-CC protein can be used as a second line
treatment in patientswith defective Jak-STATsignaling in anattempt
to stimulate an antiviral response as well as increase HLA-1
expression in hepatocytes in an IFN-c dependent manner.
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Figure 11. Intracellular expression of STAT1-CC induces p-PKR and p-eIF2a in the resistant cell line affer IFN-c treatment. The IFN-c
resistant cell line (GR17-1) was transfected with each STAT1 expression plasmid and treated with or without IFN-c. At 24 hours post-transfection
protein lysates were obtained and examined for p-PKR and p-EIF2a levels by western blot analysis. A protein lysate from the S9-13 cell line was
obtained 30 minutes after IFN-c addition and used as a positive control.
doi:10.1371/journal.pone.0013117.g011
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